Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
5.76
+0.24 (4.35%)
At close: Oct 31, 2025, 4:00 PM EDT
5.90
+0.14 (2.43%)
After-hours: Oct 31, 2025, 4:54 PM EDT
Lyra Therapeutics Revenue
Lyra Therapeutics had revenue of $183.00K in the quarter ending June 30, 2025, a decrease of -69.40%. This brings the company's revenue in the last twelve months to $770.00K, down -57.69% year-over-year. In the year 2024, Lyra Therapeutics had annual revenue of $1.53M, down -1.54%.
Revenue (ttm)
$770.00K
Revenue Growth
-57.69%
P/S Ratio
9.88
Revenue / Employee
$25,667
Employees
30
Market Cap
9.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.53M | -24.00K | -1.54% |
| Dec 31, 2023 | 1.56M | 195.00K | 14.31% |
| Dec 31, 2022 | 1.36M | 1.08M | 378.25% |
| Dec 31, 2021 | 285.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
LYRA News
- 27 days ago - Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - GlobeNewsWire
- 2 months ago - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 4 months ago - Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
- 5 months ago - Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
- 5 months ago - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewsWire
- 6 months ago - Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewsWire
- 6 months ago - Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire